Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Study Number
4173324
Phase
I
Age Group
Adult
Principal Investigator
Katherine LaVigne Mager
Purpose

This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.

Check your eligibility for this trial
Check now
Full Title

ACR-2316-101: Phase 1 Study of ACR-2316 in Subjects with Advanced Solid Tumors

ClinicalTrials.Gov ID
NCT06667141

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.